logo
logo
CLPT stock ticker logo

ClearPoint Neuro, Inc.

NASDAQ•CLPT
執行長: Mr. Joseph Michael Burnett
板塊: Healthcare
行業: Medical - Devices
上市日期: 2012-05-22
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
聯絡資訊
120 S. Sierra Avenue, Suite 100, Solana Beach, CA, 92075, United States
888-287-9109
www.clearpointneuro.com
市值
$311.17M
本益比 (TTM)
-11.6
23.8
股息率
--
52周最高
$30.10
52周最低
$8.27
52周範圍
10%
排名55Top 80.0%
2.6
F-Score
改良版 Piotroski 分析
基於 10 年期基本面
疲弱 • 2.6 / 9 分
評分區間 (0-9)
8-9: 價值優異
6-7: 基本面強勁
4-5: 整體穩健
0-3: 表現疲弱
資料區間: 2016-2025

財務儀表板

Q4 2025 數據

營業收入

$10.41M+0.00%
近4季度走勢

每股收益

-$0.27+0.00%
近4季度走勢

自由現金流

-$12.13M+0.00%
近4季度走勢

2025 Annual 財報亮點

核心亮點

Total Revenue Rises 18% Total revenue reached $37.0M USD, marking an 18% increase driven by product sales growth across segments.
Product Sales Surge 28% Product revenue grew 28% to $23.9M USD; neurosurgery disposable sales increased 44% year-over-year.
IRRAS Acquisition Closed Completed IRRAS acquisition in Q4 2025, expanding portfolio into neurocritical care with IRRAflow system integration.
Gross Margin Remains Stable Gross profit reached $22.7M USD; gross margin held steady at 61% despite increased operating costs.

關注風險

Net Loss Widens Significantly Net loss increased 35% to $(25.5M) USD in 2025; sustained profitability remains uncertain given ongoing investments.
High Customer Revenue Concentration Significant customer concentration risk exists; top five hospital customers accounted for 21% of 2025 disposable revenues.
Operating Expenses Increase General and administrative expenses rose 38% to $16.5M USD, driven by IRRAS acquisition integration costs.
Market Adoption Uncertainty Future growth hinges on achieving broad market adoption for ClearPoint and IRRAflow systems against established competitors.

未來展望

Anticipated Future Funding Needs Expect need for additional capital following IRRAS acquisition to fund commercialization and integration efforts through 2026.
Expand Installed Base Future objectives depend on expanding installed base and procedure volumes for both ClearPoint and IRRAflow platforms.
Biologics Partner Pipeline Over 60 partners evaluate products for gene/cell therapy delivery; success depends on partner clinical trial outcomes.
Cybersecurity Integration Planned Expect to fully integrate IRRAS cybersecurity governance structure and risk management framework throughout 2026.

同行對比

營業收入 (TTM)

INNV stock ticker logoINNV
$912.10M
+13.1%
VREX stock ticker logoVREX
$854.40M
+4.1%
MYGN stock ticker logoMYGN
$824.50M
-1.6%

毛利率 (最新季度)

LAB stock ticker logoLAB
83.5%
-3.2pp
SIBN stock ticker logoSIBN
79.0%
+0.8pp
AKBA stock ticker logoAKBA
78.8%
+21.3pp

關鍵指標

股票代碼
市值
本益比 (TTM)
股東權益報酬率 (TTM)
負債率
TYRA$1.88B-17.4-41.2%2.1%
AXGN$1.80B-103.9-13.4%8.7%
OLMA$1.44B-9.3-42.9%0.2%

長期趨勢

近4季度
營業收入
淨利
營運現金流
4季度營業收入複合增長率
7.1%
穩定增長
4季度淨利複合增長率
N/M
盈利狀態轉變
現金流穩定性
0%
現金流需要關注

深度研究

下次財報:2026年5月11日
|
每股收益:-
|
營業收入:-
財務數據
電話會議
財務報告
新聞
損益表
資產負債表
現金流量表
財務比率
變化率
損益表
過去12個月
無資料